Lewes, DE -- (SBWire) -- 09/25/2013 --LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: People's United Financial, Inc. (NASDAQ:PBCT), Dendreon Corporation (NASDAQ:DNDN), Omeros Corporation (NASDAQ:OMER), Opexa Therapeutics Inc (NASDAQ:OPXA).

People's United Financial, Inc. (NASDAQ:PBCT), increased/ 0.60% and closed at $14.32 on a traded volume of 2.53 million shares, in comparison to 2.57 million shares of average trading volume. So far this year, the stock is up over 18.44%.

The company has a total market capitalization of $4.60million and its total outstanding shares are 321.11million.

Will PBCT Continue To Move Higher? Find Out Here

People’s United Financial, Inc. operates as the bank holding company for People’s United Bank that provides commercial banking, retail and business banking, and wealth management services to individual, corporate, and municipal customers.

Dendreon Corporation (NASDAQ:DNDN), plunged -1.81% and closed at $2.98 on a traded volume of 2.45 million shares, whereas its average trading volume is 4.65 million shares. In the last three months, the stock is down -24.17%. The Intra-day range for the stock is $2.97 and $3.07.

Has DNDN Found The Bottom and Ready To Move Up? Find Out Here

Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics to enhance cancer treatment options for patients.

Omeros Corporation (NASDAQ:OMER), dropped down -1.31% and closed at $9.06. So far in three months, the stock is up 81.02%. The 52-week range for the stock is $3.65 and $11.85 and during the previous trading session it marked$9.65 as its highest price. The stock initially exchanged hands with a price of $9.17 and the overall traded volume that day was 2.40 million shares.

Has OMER Found The Bottom And Ready To Gain Momentum? Find Out Here

Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system.

Opexa Therapeutics Inc (NASDAQ:OPXA) after opening its shares at the price of $1.81, jumped up6.11% to close the day at $1.91. The stock ended on a traded volume of 2.40million shares, in comparison to 1.17 million shares of average trading volume. The 52-week range for the stock is $1.07 and $5.19 and during the previous trading session the stock scored the highest price of $2.06. It started the day at $1.81.

Why Should Investors Buy OPXA After The Recent Gain? Just Go Here and Find Out.

Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized cellular therapies to treat multiple sclerosis (MS) based on its proprietary T-cell technology.

About LeadingStockAlerts
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.

Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.

Disclaimer
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/